MedRx : Summary of Business Results for the Second Quarter Ended June 30, 2023 (Consolidated)

Summary of Business Results for the Second Quarter Ended June 30, 2023 [Japan GAAP](Consolidated)

		August 10, 2023
Company	Medrx Co., Ltd.	Lidted on the TSE
Stock Code	4586	URL : https://www.medrx.co.jp
Representative	Yonehiro Matsumura, President & CEO
Contact	Takeshi Fujioka, Management Department Director	TEL [phone]

Expected date of filing of annual securities report : August 10, 2023	Expected starting date of dividend payment : -
Preparation of supplementary financial document : None
Results briefing : Yes
	(Rounded down to million yen)

1. Consolidated business results for the six months ended June 2023 (January 1, 2023 through June 30, 2023)

(1) Consolidated results of operations			(% change from the previous corresponding period)
	Net sales	Operating income	Ordinary income	Profit attributable to
	owners of parent
	Million
	yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended Jun. 2023	6	-26.6	-478	-	-480	-	-481	-
Six months ended Jun. 2022	9	26.7	-374	-	-382	-	-381	-
(Note) Comprehensive income:
Six months ended June 2023 : -484 million yen (-%)
Six months ended June 2022 : -377 million yen (-%)
	Net income	Diluted net
	Per share	Income per shar
		Yen		Yen
Six months ended Jun. 2023		-14.97	-
Six months ended Jun. 2022		-15.50	-
(Note) Diluted net income per share is not applicable due to net loss share
(2) Consolidated financial position
	Total assets	Net assets	Shareholders' equity
	ratio
	Million yen	Million yen	%
As of Jun. 2023		1,736		1,680		93.0
As of Dec. 2022		1,398		1,212		82.2
(Reference) Shareholders' equity :
As of June 2023 : 1,615 million yen
As of December 2022 : 1,148 million yen
2. Dividends
				Annual dividend
	End of 1Q	End of 2Q		End of 3Q	Year-end	Total
		Yen		Yen	Yen		Yen	Yen
Year ended Dec. 2022		-		0.00	-		0.00	0.00
Year ended Dec. 2023		-		0.00
Year ended Dec. 2023 (forecast)					-		0.00	0.00

(Note) Revisions to dividend forecast for the current quarter: None

3. Forecast of consolidated business results for the fiscal year ending December 2023 (January 1, 2023 through December 31, 2023)

							(% change from the previous year)
	Net sales		Operating income	Ordinary income	Net income	Net income
		Per share
	Million y		Million y		Million y		Million y
	en	%	en	%	en	%	en	%	Yen
Year ending Dec. 2023	127	214.9	-830	-	-783	-	-786	-	-22.34

(Note) Revisions to business forecast for the current quarter: None

―1―

• Notes
• 1. Changes in significant subsidiaries during the period : None
  2. Application of accounting procedures specific to preparation of the consolidated quarterly financial statements : None
  3. Change in accounting policies, accounting estimates and restatement

①	Changes in accounting policies associated with revision of accounting standards:	: None
②	Changes in accounting policies other than ①	: None
③	Changes in accounting estimates	: None
④	Restatement	: None

1. Shares outstanding (common stock)
   ① Number of share outstanding at the end of period (treasury stock included) :

As of June 2023	35,205,100 shares
As of December 2022	28,224,100 shares

• Treasury stock at the end of period :

As of June 2023	1 share
As of December 2022	1 share

• Average number of stock during period :

Six months ended June 2023	32,184,566 shares
Six months ended June 2022	24,595,100 shares

• This report is not subject to auditing by a certified public accountant or an audit corporation.
• Explanation regarding appropriate use of business forecasts and other special instructions

Forecasts regarding future performance in this material are based on information currently available to the company and certain assumptions that the company deems to be reasonable at the time this report was prepared. The company does not make promises about the achievements. Actual results may differ significantly from the forecasts due to various factors.

―2―